HCIT Platform
🛡️ Public data only — no PHI permitted on this instance.
HCIT / SaaS Platform Analyzer
ARR · NRR · LTV/CAC · Rule of 40 · TAM · public/private comp universe — 1,600 corpus deals
Total ARR
$84.2M
Growth YoY
+38.0%
NRR
1.11x
Gross Margin
78.0%
Rule of 40
52
Magic Number
1.35
Customers
682
Corpus Deals
1,600
Customer Segment Economics
| Segment | Customers | ACV ($k) | ARR ($M) | NRR | Gross Churn | LTV ($k) | CAC Payback (mo) |
|---|---|---|---|---|---|---|---|
| Large Health Systems (>$1B) | 35 | $425.0 | $14.88 | 1.12x | 2.0% | $2,850 | 14 |
| Regional Health Systems | 85 | $165.0 | $14.03 | 1.08x | 4.0% | $1,180 | 17 |
| Medical Groups (200+ providers) | 245 | $62.0 | $15.19 | 1.06x | 6.0% | $485 | 19 |
| ASC / Specialty Networks | 185 | $32.0 | $5.92 | 1.04x | 8.0% | $285 | 22 |
| Payers (MA / Commercial) | 42 | $385.0 | $16.17 | 1.15x | 3.0% | $2,620 | 15 |
| PE-Backed Platforms | 68 | $185.0 | $12.58 | 1.18x | 5.0% | $1,485 | 13 |
| Academic Medical Centers | 22 | $245.0 | $5.39 | 1.05x | 2.0% | $1,820 | 20 |
Product Line Portfolio
| Product | Category | ARR ($M) | YoY Growth | Gross Margin | Users |
|---|---|---|---|---|---|
| Core Analytics Platform | Analytics | $32.50 | +28.0% | 82.0% | 850 |
| Population Health Module | Clinical | $18.50 | +42.0% | 78.0% | 420 |
| Quality Measures Reporting | Regulatory | $12.50 | +22.0% | 85.0% | 620 |
| Payer Contract Analytics | Financial | $8.50 | +55.0% | 80.0% | 185 |
| Risk Adjustment / HCC Coding | Clinical | $10.50 | +68.0% | 75.0% | 340 |
| Clinical Trial Matching | Research | $4.50 | +85.0% | 82.0% | 125 |
| Provider Directory / Credentialing | Admin | $6.80 | +18.0% | 88.0% | 480 |
SaaS Benchmark Metrics
| Metric | Current | Top Quartile | Median | Percentile |
|---|---|---|---|---|
| ARR Growth YoY | 38.0% | 45.0% | 25.0% | P72 |
| Net Revenue Retention | 1.12x | 1.20x | 1.05x | P62 |
| Gross Revenue Retention | 0.94x | 0.96x | 0.88x | P68 |
| Gross Margin | 78.0% | 85.0% | 72.0% | P70 |
| Rule of 40 | 52.0% | 65.0% | 40.0% | P68 |
| Magic Number | 1.35x | 1.50x | 0.85x | P72 |
| CAC Payback Months | 17.0 | 13.0 | 21.0 | P68 |
| LTV / CAC | 5.20x | 6.50x | 3.80x | P65 |
| FCF Margin | 14.0% | 25.0% | 5.0% | P68 |
| Sales Efficiency | 0.82x | 1.10x | 0.60x | P65 |
Sub-TAM Penetration & Revenue Opportunity
| Sub-TAM | TAM ($M) | Serviceable ($M) | Current Penetration | Y3 Target | Revenue Opportunity ($M) |
|---|---|---|---|---|---|
| Provider Analytics Platform | $8,500 | $3,200 | 0.90% | 4.50% | $115.20 |
| Payer Risk Adjustment | $4,200 | $1,650 | 0.60% | 3.20% | $42.90 |
| Quality Reporting / Stars | $2,800 | $1,050 | 1.20% | 5.50% | $45.20 |
| Clinical Trial Recruitment | $1,850 | $580 | 0.80% | 3.50% | $15.70 |
| Population Health Management | $5,200 | $2,100 | 0.90% | 4.20% | $69.30 |
| Value-Based Care Enablement | $3,400 | $1,250 | 1.00% | 4.80% | $47.50 |
Public & Private Comp Universe
| Company | ARR ($M) | Growth | EV/Rev Mult | Implied EV ($M) | Profile |
|---|---|---|---|---|---|
| Veeva Systems (public) | $2,850 | +16.0% | 12.50x | $35,625 | life-sci SaaS leader |
| Doximity (public) | $510 | +18.0% | 8.20x | $4,182 | physician network monetization |
| Definitive Healthcare (public) | $285 | +8.0% | 3.80x | $1,083 | provider data / commercial intel |
| Health Catalyst (public) | $290 | +4.0% | 2.50x | $725 | analytics / data warehouse |
| HealthEdge (PE / Bain) | $425 | +32.0% | 12.00x | $5,100 | payer core system |
| Cotiviti (PE / Veritas) | $1,250 | +14.0% | 8.80x | $11,000 | payer analytics / integrity |
| Clario (PE / Astorg/Nordic) | $725 | +22.0% | 9.50x | $6,888 | clinical trial tech |
| Evolent (public) | $2,150 | +35.0% | 3.20x | $6,880 | VBC enablement |
| Signify Health (CVS acq) | $900 | +42.0% | 10.50x | $9,450 | in-home clinical visits |
| Olive AI (shutdown 2023) | $0 | -100.0% | 0.00x | $0 | cautionary tale / RIP |
HCIT SaaS Thesis: $84.2M ARR growing +38% with 1.11x NRR and 78% gross margin.
Rule of 40 at 52 places platform in top third of healthcare SaaS; magic number 1.35 signals efficient growth.
Large health system / payer / PE-backed customer segments generate highest LTV and NRR (1.12-1.18x) — expansion motion is a reliable revenue compounder.
Aggregate TAM opportunity $336M over 3-year horizon across 6 sub-markets.
Public comp set trades 3-13x EV/Revenue depending on growth/margin profile; private comps (Cotiviti, HealthEdge, Clario) support premium exit multiples for scaled platforms with defensible data assets.